VTRS
BalancerViatris
$13.83
+2.67%
as of 13 Apr
Power Core
Viatris's moat is the sheer breadth of its global distribution infrastructure across 165 countries, paired with a portfolio of 1,400-plus molecules that no single competitor can replicate at equivalent scale.
Direction of Movement
Lateral: Between Restructuring Completion and Growth Proof
ROC 200
+49.5%
VTRS
Viatris
$13.83
+2.67%
as of 13 Apr
DCF Fair Value: $27.81
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Viatris Inc. is a global healthcare company that develops, manufactures, and markets a broad portfolio of branded and generic pharmaceutical products. It specializes in generics, including commoditized and complex varieties as well as biosimilars, alongside legacy branded medicines such as Lipitor, Norvasc, Lyrica, and Viagra. The company addresses multiple therapeutic areas, including cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare, with particular focus on dermatology, ophthalmology, and gastroenterology. Viatris Inc. serves patients in over 165 countries through its extensive product offerings in the specialty and generic drug sectors. Founded in 2019 and headquartered in Canonsburg, Pennsylvania, it operates as one of the largest generic drug manufacturers worldwide, providing essential medicines and treatments to diverse healthcare markets.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
30,000
Website
https://www.viatris.com